{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:42:17Z","timestamp":1784612537033,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673510"],"award-info":[{"award-number":["81673510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073936"],"award-info":[{"award-number":["82073936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015226","name":"Shengjing Hospital of China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000100","name":"Toronto Arts Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000100","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.intimp.2023.110866","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T07:09:10Z","timestamp":1693897750000},"page":"110866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"PA","title":["Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-0845","authenticated-orcid":false,"given":"Cheng-Bin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.intimp.2023.110866_b0005","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic Lupus Erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110866_b0010","first-page":"172","article-title":"2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"59","author":"Mengtao","year":"2020","journal-title":"Rheumatol. Immunol. Res."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2023.110866_b0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.trim.2009.07.001","article-title":"Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects","volume":"22","author":"Rauch","year":"2009","journal-title":"Transpl. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ibd\/izz068","article-title":"Tacrolimus therapy in steroid-refractory ulcerative colitis: a review","volume":"26","author":"Wu","year":"2020","journal-title":"Inflamm. Bowel. Dis"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2147\/DDDT.S41349","article-title":"Tacrolimus in preventing transplant rejection in Chinese patients\u2013optimizing use","volume":"9","author":"Li","year":"2015","journal-title":"Drug. Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0961203315600538","article-title":"The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study","volume":"25","author":"Watanabe","year":"2016","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0035","doi-asserted-by":"crossref","first-page":"e000274","DOI":"10.1136\/lupus-2018-000274","article-title":"Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres","volume":"5","author":"Tani","year":"2018","journal-title":"Lupus. Sci. Med"},{"issue":"2","key":"10.1016\/j.intimp.2023.110866_b0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/jcpt.13072","article-title":"Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule","volume":"45","author":"Chen","year":"2020","journal-title":"J. Clin. Pharm. Ther"},{"issue":"4","key":"10.1016\/j.intimp.2023.110866_b0045","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jcpt.12707","article-title":"Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study","volume":"43","author":"Wang","year":"2018","journal-title":"J. Clin. Pharm. Ther"},{"issue":"10","key":"10.1016\/j.intimp.2023.110866_b0050","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin. Pharmacokinet"},{"issue":"2","key":"10.1016\/j.intimp.2023.110866_b0055","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/aps.2014.110","article-title":"A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients","volume":"36","author":"Lu","year":"2015","journal-title":"Acta. Pharmacol. Sin"},{"issue":"6","key":"10.1016\/j.intimp.2023.110866_b0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr. Drug. Metab"},{"issue":"6","key":"10.1016\/j.intimp.2023.110866_b0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cca.2015.03.021","article-title":"ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis","volume":"445","author":"Naito","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"3\u20134","key":"10.1016\/j.intimp.2023.110866_b0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.phymed.2012.11.008","article-title":"Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus","volume":"20","author":"Qin","year":"2013","journal-title":"Phytomedicine"},{"issue":"10","key":"10.1016\/j.intimp.2023.110866_b0075","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e31826c3985","article-title":"NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation","volume":"94","author":"Barraclough","year":"2012","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.intimp.2023.110866_b0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr. Rev"},{"issue":"3","key":"10.1016\/j.intimp.2023.110866_b0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11095-019-2579-6","article-title":"Dosage optimization based on population pharmacokinetic analysis of tacrolimus in chinese patients with nephrotic syndrome","volume":"36","author":"Lu","year":"2019","journal-title":"Pharm. Res"},{"issue":"5","key":"10.1016\/j.intimp.2023.110866_b0090","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/FTD.0000000000001008","article-title":"Tacrolimus population pharmacokinetic model in adult chinese patients with nephrotic syndrome and dosing regimen identification using Monte Carlo simulations","volume":"44","author":"Minghao","year":"2022","journal-title":"Ther. Drug. Monit."},{"issue":"12","key":"10.1016\/j.intimp.2023.110866_b0095","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/0091270011423661","article-title":"A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation","volume":"52","author":"Musuamba","year":"2012","journal-title":"J. Clin. Pharmacol"},{"issue":"9","key":"10.1016\/j.intimp.2023.110866_b0100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40262-013-0069-2","article-title":"Multidrug resistance-associated protein 2 (MRP2\/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients","volume":"52","author":"Ogasawara","year":"2013","journal-title":"Clin. Pharmacokinet"},{"issue":"5","key":"10.1016\/j.intimp.2023.110866_b0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FPC.0b013e32835fcbb6","article-title":"Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis","volume":"23","author":"Zuo","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"issue":"11","key":"10.1016\/j.intimp.2023.110866_b0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.intimp.2023.110866_b0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-012-0007-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation","volume":"51","author":"Bergmann","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.intimp.2023.110866_b0120","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","article-title":"Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation","volume":"18","author":"Anglicheau","year":"2003","journal-title":"Nephrol. Dial. Transplant"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.genm.2011.01.003","article-title":"Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients","volume":"8","author":"Velickovic-Radovanovic","year":"2011","journal-title":"Gend. Med"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"Storset","year":"2014","journal-title":"Eur. J. Clin. Pharmacol"},{"issue":"5","key":"10.1016\/j.intimp.2023.110866_b0135","first-page":"4023","article-title":"Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models","volume":"17","author":"Wang","year":"2019","journal-title":"Exp. Ther. Med"},{"issue":"8","key":"10.1016\/j.intimp.2023.110866_b0140","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/aps.2016.174","article-title":"Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients","volume":"38","author":"Chen","year":"2017","journal-title":"Acta. Pharmacol. Sin"},{"issue":"11","key":"10.1016\/j.intimp.2023.110866_b0145","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","article-title":"Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review","volume":"59","author":"Kirubakaran","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0150","article-title":"Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model","volume":"143","author":"Huang","year":"2020","journal-title":"Eur. J. Pharm. Sci"},{"issue":"9","key":"10.1016\/j.intimp.2023.110866_b0155","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann. Rheum. Dis"},{"issue":"4","key":"10.1016\/j.intimp.2023.110866_b0160","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjsurg.2017.01.026","article-title":"Exploring the usage of a mobile phone application in transplanted patients to encourage medication compliance and education","volume":"214","author":"Zanetti-Yabur","year":"2017","journal-title":"Am. J. Surg"},{"issue":"6","key":"10.1016\/j.intimp.2023.110866_b0165","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0000000000000563","article-title":"A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy","volume":"40","author":"Chen","year":"2018","journal-title":"Ther. Drug. Monit"},{"issue":"11","key":"10.1016\/j.intimp.2023.110866_b0170","article-title":"Tacrolimus pharmacokinetics in pediatric nephrotic syndrome: A combination of population pharmacokinetic modelling and machine learning approaches to improve individual prediction","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Pharmacol"},{"issue":"3","key":"10.1016\/j.intimp.2023.110866_b0175","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CP203355","article-title":"Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome","volume":"57","author":"Wang","year":"2019","journal-title":"Int. J. Clin. Pharmacol. Ther"},{"issue":"4","key":"10.1016\/j.intimp.2023.110866_b0180","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13318-020-00609-5","article-title":"Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study","volume":"45","author":"Liu","year":"2020","journal-title":"Eur. J. Drug. Metab. Pharmacokinet"},{"issue":"6","key":"10.1016\/j.intimp.2023.110866_b0185","first-page":"4653","article-title":"Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: Initial dosage recommendations","volume":"18","author":"Wang","year":"2019","journal-title":"Exp. Ther. Med"},{"issue":"5","key":"10.1016\/j.intimp.2023.110866_b0190","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00228-018-2414-8","article-title":"Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling","volume":"74","author":"Xu","year":"2018","journal-title":"Eur. J. Clin. Pharmacol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00265-010-1029-6","article-title":"AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons","volume":"65","author":"Burnham","year":"2010","journal-title":"Behav. Ecol. Sociobiol"},{"issue":"7","key":"10.1016\/j.intimp.2023.110866_b0200","first-page":"e51","article-title":"Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacometr. Syst. Pharmacol"},{"issue":"3","key":"10.1016\/j.intimp.2023.110866_b0205","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"MERC\u00e8","year":"2019","journal-title":"Ther. Drug. Monit."},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0210","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: A systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun. Rev"},{"issue":"3","key":"10.1016\/j.intimp.2023.110866_b0215","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.berh.2017.09.010","article-title":"Calcineurin inhibitors in systemic lupus erythematosus","volume":"31","author":"Mok","year":"2017","journal-title":"Best. Pract. Res. Clin. Rheumatol"},{"issue":"8","key":"10.1016\/j.intimp.2023.110866_b0220","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","article-title":"Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis","volume":"79","author":"Mok","year":"2020","journal-title":"Ann. Rheum. Dis"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann. Rheum. Dis"},{"issue":"2","key":"10.1016\/j.intimp.2023.110866_b0230","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3892\/etm.2020.8821","article-title":"Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real world data","volume":"20","author":"Chen","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0235","first-page":"110","article-title":"Population pharmacokinetic analysis of oral tacrolimus in patients with glomerulonephritis","volume":"1","author":"Shim","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther"},{"issue":"9","key":"10.1016\/j.intimp.2023.110866_b0240","article-title":"Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome","volume":"98","author":"Li","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110866_b0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1515\/dmpt-2016-0036","article-title":"Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients","volume":"32","author":"Tamashiro","year":"2017","journal-title":"Drug. Metab. Pers. Ther"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0250","article-title":"CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation","volume":"809","author":"Dong","year":"2022","journal-title":"Gene"},{"issue":"15","key":"10.1016\/j.intimp.2023.110866_b0255","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2217\/pgs-2019-0090","article-title":"Impact of CYP3A4\/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome","volume":"20","author":"Lingfei","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.intimp.2023.110866_b0260","first-page":"187","article-title":"Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient","volume":"81","author":"C\u00e9LINE","year":"2006","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.intimp.2023.110866_b0265","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/FTD.0b013e318271b6e6","article-title":"Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole","volume":"34","author":"Wei","year":"2012","journal-title":"Ther. Drug. Monit"},{"issue":"5","key":"10.1016\/j.intimp.2023.110866_b0270","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/00498254.2019.1669844","article-title":"Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule","volume":"50","author":"Chen","year":"2020","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.intimp.2023.110866_b0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transplant. Rev. (Orlando)"},{"issue":"2","key":"10.1016\/j.intimp.2023.110866_b0280","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/FTD.0b013e31824a67eb","article-title":"The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients","volume":"34","author":"Xiao-Qing","year":"2012","journal-title":"Ther. Drug. Monit"},{"issue":"5","key":"10.1016\/j.intimp.2023.110866_b0285","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bcp.12830","article-title":"External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients","volume":"81","author":"Zhao","year":"2016","journal-title":"Br. J. Clin. Pharmacol"},{"issue":"2","key":"10.1016\/j.intimp.2023.110866_b0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","article-title":"Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients","volume":"31","author":"Rogier","year":"2009","journal-title":"Ther. Drug. Monit"},{"issue":"7","key":"10.1016\/j.intimp.2023.110866_b0295","article-title":"Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy","volume":"169","author":"Wang","year":"2021","journal-title":"Pharmacol. Res"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"Laure","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.intimp.2023.110866_b0305","first-page":"207","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Christine","year":"2010","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.intimp.2023.110866_b0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2014.129","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk","year":"2014","journal-title":"Clin. Pharmacol. Ther"},{"issue":"9","key":"10.1016\/j.intimp.2023.110866_b0315","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/jcph.1118","article-title":"Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients","volume":"58","author":"Campagne","year":"2018","journal-title":"J. Clin. Pharmacol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110866_b0320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1067\/mcp.2001.113183","article-title":"The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups","volume":"69","author":"Mancinelli","year":"2001","journal-title":"Clin. Pharmacol. Ther"},{"issue":"9","key":"10.1016\/j.intimp.2023.110866_b0325","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2020.1803277","article-title":"Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives","volume":"16","author":"Degraeve","year":"2020","journal-title":"Expert. Opin. Drug. Metab. Toxicol"},{"issue":"8","key":"10.1016\/j.intimp.2023.110866_b0330","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3389\/fgene.2020.00889","article-title":"Beyond single nucleotide polymorphisms: CYP3A5*3*6*7 composite and ABCB1 haplotype associations to tacrolimus pharmacokinetics in black and white renal transplant recipients","volume":"11","author":"Brazeau","year":"2020","journal-title":"Front. Genet"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923011918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923011918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:02:33Z","timestamp":1761588153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923011918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":66,"alternative-id":["S1567576923011918"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110866","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110866"}}